Salarius Pharmaceuticals Inc Stock Price, News & Analysis

Salarius Pharmaceuticals (SLRX) reported a net loss of $3.7 million or $0.08 per share for Q3 2021, an increase from $1.7 million in the same period last year. The total working capital stood at $33.6 million, bolstered by a $2.7 million disbursement from CPRIT. The company is progressing with clinical trials for its lead drug candidate, seclidemstat, with 13 active sites now supporting enrollment. The Ewing sarcoma safety lead-in cohort is fully enrolled, and seclidemstat's development pipeline is expanding with new collaborations and clinical sites.

Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call on November 4, 2021, at 5:00 p.m. ET to discuss its corporate and financial results for Q3 2021. The call can be accessed via phone or online, with an archive available for 90 days post-event. Salarius is focused on developing treatments for cancers with high unmet medical needs, including their lead candidate, seclidemstat, currently in clinical trials for Ewing sarcoma and other cancers. The company has received multiple designations from the FDA, highlighting its commitment to advancing oncology treatments.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) presented significant preclinical findings at the 2021 AACR-NCI-EORTC Conference, focusing on its lead drug candidate, seclidemstat (SP-2577). The research highlights seclidemstat's unique action against FET-rearranged sarcomas, showcasing potent activity in preclinical models, especially in Ewing sarcoma and desmoplastic small round cell tumors. The data suggests seclidemstat's differentiated mechanism exceeds other LSD1 inhibitors, leading to a strategic amendment in its ongoing Phase 1/2 trial to include FET-rearranged sarcoma patients. Further studies aim to identify biomarkers for treatment sensitivity.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present virtually at the 2021 BioFuture Conference on October 5-6 in New York City. His presentation will cover the company's clinical achievements and future milestones for seclidemstat, an oral LSD1 inhibitor. Seclidemstat is undergoing a Phase 1/2 trial for Ewing sarcoma and another trial for hematologic cancers. Interested investors can register here. A recording will later be available on the company's website.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced a significant achievement as its abstract on seclidemstat's potential in treating FET-rearranged sarcomas was accepted for presentation at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The research highlights seclidemstat’s mechanism of inhibiting the LSD1 enzyme, a promising area in cancer treatment. Salarius is currently evaluating seclidemstat in clinical trials for various cancers, including Ewing sarcoma.

Salarius Pharmaceuticals (Nasdaq: SLRX) has received a $2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas (CPRIT) to support its lead drug candidate, seclidemstat. This funding adds to the $33 million already reported on its balance sheet as of June 30, 2021, with up to $2.1 million remaining under the original CPRIT award. Seclidemstat is being studied for various cancers, including Ewing sarcoma, with clinical trials underway across five patient groups.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 10:50 a.m. ET. The event will be accessible virtually to registered attendees. Arthur will discuss Salarius’ recent achievements and highlight the clinical trial for seclidemstat, an oral LSD1 inhibitor, which is targeting Ewing sarcoma and other cancers. The company also plans virtual one-on-one meetings with investors. A recording of the presentation will be available on Salarius’ website post-event.

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced a partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to explore new indications and potential biomarkers for its lead drug candidate, seclidemstat. This oral inhibitor targets lysine-specific histone demethylase 1 (LSD1), a key enzyme in cancer progression. A Phase 1/2 trial is ongoing for sarcomas and now includes hematologic cancers. CEO David Arthur emphasized the collaboration as a validation of seclidemstat's potential and aims to provide new treatment options for patients with difficult-to-treat cancers.

Salarius Pharmaceuticals (Nasdaq: SLRX) has been included in the FTSE Global Micro Cap Index, effective September 20, 2021. This milestone is aimed at enhancing the company's visibility among institutional investors and increasing stock liquidity, as noted by CEO David Arthur. The FTSE Global Micro Cap Index comprises 8,832 companies with a net market capitalization of $1.89 trillion, with 47% of its constituents based in the U.S. and 17.65% from the healthcare sector. This inclusion signals a positive year for Salarius, aligned with its ongoing clinical programs.